{"url":"https://lda.senate.gov/api/v1/filings/1f4ae6d2-e42c-4fcb-a46b-018c8393adca/","filing_uuid":"1f4ae6d2-e42c-4fcb-a46b-018c8393adca","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2021,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/1f4ae6d2-e42c-4fcb-a46b-018c8393adca/print/","filing_document_content_type":"text/html","income":null,"expenses":"90000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"James R Kasinger","dt_posted":"2022-01-18T18:34:32.190000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"610 Main Street","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Cambridge","registrant_state":"MA","registrant_zip":"02139","registrant":{"id":401105184,"url":"https://lda.senate.gov/api/v1/registrants/401105184/","house_registrant_id":44327,"name":"CRISPR THERAPEUTICS, INC.","description":"Biotech","address_1":"105 W First St","address_2":null,"address_3":null,"address_4":null,"city":"Boston","state":"MA","state_display":"Massachusetts","zip":"02127","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JAMES KASINGER","contact_telephone":"+1 617-315-4526","dt_updated":"2026-02-27T08:33:23.911411-05:00"},"client":{"id":203367,"url":"https://lda.senate.gov/api/v1/clients/203367/","client_id":12,"name":"CRISPR THERAPEUTICS, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-08-31"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Coverage & reimbursement for Cell and Gene Therapies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":108026,"prefix":null,"prefix_display":null,"first_name":"CASEY","nickname":null,"middle_name":null,"last_name":"CALDWELL","suffix":null,"suffix_display":null},"covered_position":"Head of Government Affairs","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Coverage & reimbursement for Cell and Gene Therapies\nAllogeneic CAR-T","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":108026,"prefix":null,"prefix_display":null,"first_name":"CASEY","nickname":null,"middle_name":null,"last_name":"CALDWELL","suffix":null,"suffix_display":null},"covered_position":"Head of Government Affairs","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Reimbursement for cell and gene therapies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":108026,"prefix":null,"prefix_display":null,"first_name":"CASEY","nickname":null,"middle_name":null,"last_name":"CALDWELL","suffix":null,"suffix_display":null},"covered_position":"Head of Government Affairs","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}